Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
type: Dataset
description: International audience
issued: 2026-05-15T12:31:50.932847
language: en
modified: 2026-05-15T12:31:50.932853
contact point: Organization
  fn: CCSD
keyword: infoeu-reposemanticsarticle
keyword: journal-articles
keyword: mesh-aged
keyword: mesh-aged-80-and-over
keyword: mesh-anemia-refractory-with-excess-of-blasts
keyword: mesh-antineoplastic-combined-chemotherapy-protocols
keyword: mesh-boronic-acids
keyword: mesh-cytarabine
keyword: mesh-drug-administration-schedule
keyword: mesh-drug-therapy-combination
keyword: mesh-female
keyword: mesh-follow-up-studies
keyword: mesh-humans
keyword: mesh-leukemia-myeloid-acute
keyword: mesh-male
keyword: mesh-middle-aged
keyword: mesh-myelodysplastic-syndromes
keyword: mesh-pyrazines
keyword: mesh-survival-analysis
keyword: mesh-treatment-outcome
keyword: sdvbddlife-sciences-q-biodevelopment-biology
landing page: 0007-1048

Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
type: Distribution
format: HTML
issued: 2026-05-15T12:31:51.006572
modified: 2026-05-15T12:31:50.893201
access URL: https://hal.science/hal-00771197

test_moissonnage_selune
type: Agent